Literature DB >> 20791323

Mycological and clinical evaluation of griseofulvin for chronic onychomycosis.

R R Davies, J D Everall, E Hamilton.   

Abstract

Entities:  

Year:  1967        PMID： 20791323      PMCID： PMC1842694          DOI： 10.1136/bmj.3.5563.464

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  8 in total

1.  GRISEOFULVIN ADMINISTRATION AND PORPHYRIN METABOLISM. A SURVEY.

Authors:  C RIMINGTON; P N MORGAN; K NICHOLLS; J D EVERALL; R R DAVIES
Journal:  Lancet       Date:  1963-08-17       Impact factor: 79.321

2.  Storage and retrieval of biological information.

Authors:  G C AINSWORTH
Journal:  Nature       Date:  1961-07-01       Impact factor: 49.962

3.  Disturbance of porphyrin metabolism caused by griseofulvin in mice.

Authors:  F DE MATTEIS; C RIMINGTON
Journal:  Br J Dermatol       Date:  1963-03       Impact factor: 9.302

4.  Presence of griseofulvin in hair of guinea pigs after oral administration.

Authors:  J C GENTLES; M J BARNES; K H FANTES
Journal:  Nature       Date:  1959-01-24       Impact factor: 49.962

5.  Some cytological effects of griseofulvin.

Authors:  G E PAGET; A L WALPOLE
Journal:  Nature       Date:  1958-11-08       Impact factor: 49.962

6.  Griseofulvin for the systemic treatment of dermatomycoses.

Authors:  H BLANK; J G SMITH; F J ROTH; N ZAIAS
Journal:  J Am Med Assoc       Date:  1959-12-19

7.  Oral treatment of ringworm with griseofulvin.

Authors:  D I WILLIAMS; R H MARTEN; I SARKANY
Journal:  Lancet       Date:  1958-12-06       Impact factor: 79.321

8.  Experimental ringworm in guinea pigs: oral treatment with griseofulvin.

Authors:  J C GENTLES
Journal:  Nature       Date:  1958-08-16       Impact factor: 49.962
  8 in total
  16 in total

Review 1.  Onychomycosis in the elderly.

Authors:  A K Gupta
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

Review 2.  Onychomycosis. Going for cure.

Authors:  A K Gupta; N H Shear
Journal:  Can Fam Physician       Date:  1997-02       Impact factor: 3.275

Review 3.  A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.

Authors:  A K Gupta; N H Shear
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

Review 4.  Clinical and economic factors in the treatment of onychomycosis.

Authors:  T R Einarson; A K Gupta; N H Shear; S Arikian
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

Review 5.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Mycological tests and onychomycosis.

Authors:  R R Davies
Journal:  J Clin Pathol       Date:  1968-11       Impact factor: 3.411

Review 7.  Terbinafine. A pharmacoeconomic evaluation of its use in superficial fungal infections.

Authors:  R Davis; J A Balfour
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

Review 8.  Fungal nail disease: a guide to good practice (report of a Working Group of the British Society for Medical Mycology).

Authors:  D W Denning; E G Evans; C C Kibbler; M D Richardson; M M Roberts; T R Rogers; D W Warnock; R E Warren
Journal:  BMJ       Date:  1995-11-11

9.  Fungal infections of the nails in Western Australia.

Authors:  R McAleer
Journal:  Mycopathologia       Date:  1981-02-13       Impact factor: 2.574

Review 10.  Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections.

Authors:  M Haria; H M Bryson
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.